Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OATD 01

Next Previous
Drug Profile

OATD 01

Alternative Names: GLP 4716; GLPG-4716; OAT-889; OATD 01

Latest Information Update: 18 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yale University
  • Developer Molecure
  • Class Amines; Antiasthmatics; Antifibrotics; Chlorobenzenes; Hepatoprotectants; Morpholines; Nonsteroidal anti-inflammatories; Piperidines; Small molecules; Triazoles
  • Mechanism of Action Acidic mammalian chitinase inhibitors; Chitotriosidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis; Sarcoidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pulmonary sarcoidosis
  • Phase I Interstitial lung diseases
  • Preclinical Non-alcoholic steatohepatitis
  • Research Fibrosis
  • No development reported Asthma; Chronic obstructive pulmonary disease
  • Discontinued Idiopathic pulmonary fibrosis

Most Recent Events

  • 28 Mar 2025 Preclinical trials in Non-alcoholic steatohepatitis in Poland (PO)
  • 28 Mar 2025 Molecure plans phase-II trial for Non-alcoholic steatohepatitis (PO)
  • 28 Sep 2024 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in Poland (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top